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Purpose: This exploratory study examined the relationship between performance on the
University of Pennsylvania Smell Identification Test (UPSIT) and the Addenbrooke’s Cognitive
Examination (ACE) to identify a possible association between olfaction and mild cognitive
impairment(MCI).
Design and Methods: 54 community-dwelling older (ages 49–91) volunteers were given the
UPSIT and ACE.
Results: The ACE identified 7 subjects (13%) who had probable MCI. UPSIT total scores were
significantly related to ACE total scores (r = 0.37, p = 0.005). Four specific odorants (mint,
lime, chocolate, and cheddar cheese) from the UPSIT identified 4 of the 7 (57.1%) probable
MCI subjects. The prevalence rate of MCI in subjects over 65 was 19.4%.
Implications: Selective odorants in UPSIT used with ACE show promise as a non-invasive
method of detecting MCI in community dwelling elders. Detection of MCI could facilitate
earlier interventions and treatment of dementia.
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Introduction
This exploratory study grew out of a perceived need by the authors (pharmacist,
occupational therapist, pharmacologist, and geropsychiatric nurse practitioner) to
develop a non-invasive, easy-to-use tool for identifying community dwelling older
adults with mild cognitive impairment (MCI). Our practices show that instruments
used in health care settings often fail to detect small changes in cognition resulting in
delayed diagnosis of mental decline. These delays reduce or eliminate the opportunity
to make crucial life decisions such as health, financial, and housing decisions plus
postpone early pharmacological treatments to slow declines associated with dementia.
In this paper, we discuss the concept of MCI and olfactory deficits associated with
cognition. In the methods section, we describe our study subjects, community dwelling
elders who volunteered to take two tests: the Addenbrooke’s Cognitive Examination
(ACE) and the University of Pennsylvania Smell Identification Test (UPSIT). We also
describe data collection and analysis methods, and present and discuss our study results.
Background
MCI
Considerable evidence documents the predictive value of individuals diagnosed with
MCI (Knopman et al 2000; Relkin 2000) and the eventual progression to a diagnosis of
dementia (Petersen et al 2001a; Bennett et al 2002). Petersen et al (2001a) describe
mild cognitive impairment as “mildly impaired individuals who may be in a transitional
stage between normal aging and dementia” (p. 1134). MCI criteria are (1) memory
complaint, preferably corroborated by an informant; (2) objective memory impairment
that is abnormal for age and educational background; (3) normal general cognitive function;
(4) intact activities of daily living; (5) absence of [diagnosed] dementia (Petersen et alNeuropsychiatric Disease and Treatment 2006:2(4) 566
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2001a). There are many concepts used to describe age-
associated cognitive decline (Crook et al 1986) but not all lead
to dementia (Hanninen 1996). However, studies from clinic-
based practices have reported that approximately 44% of
individuals diagnosed with MCI convert to dementia over a
three-year follow-up period, demonstrating an annual
conversion rate of 10% to 15% of individuals per year
(Grundman et al 1996). This is consistent with a more recent
study showing an annual conversion rate from MCI to
dementia of 12% (Petersen et al 2001b). Research (Knopman
et al 2000; Bennett et al 2002; Tabert et al 2006) shows the
progression of cognitive decline from a recognition of early
signs of disease by care givers to the development of defined
symptoms of dementia by healthcare providers to be between
3 and 4 years, opening a window for possible early
interventions.
Interventions include the monitoring of activities of daily
living such as financial management, estate planning, driving
ability, medical advance directives, housing, and mobility
(Hogan and McKeith 2001; Karlawish and Clark 2003).
Interventions may also include medications such as
anticholinesterase or nootropic agents that show potential in
slowing the progression of selected dementias and possibly
enhancing cognition (Zanni and Wick 2002).
Early detection of MCI is challenging as there is still
limited and conflicting information on normal age-related
cognitive and sensory changes. For example, the rate of age-
associated anosmia, the loss of the sense of smell, has been
reported between 5% and 50% in individuals 60–90 years of
age but specific causes for the deficits can be difficult to
identify. Common diseases and commonly used medications
can cause anosmia (Ackerman and Kasbekar 1997).
Olfaction
Studies by several investigators (Doty 1995; Devanand et al
2000) show a relationship between olfaction and dementia.
Doty (1995) used the inability to select odorants to identify
individuals with dementia using the UPSIT. Recent studies
(Devanand et al 2000) identified a characteristic deficit in
the olfactory sense associated with dementia. Graves and
colleagues (1999) found a smell identification test detected
cognitive decline better than a test of global cognition. This
decline in the sense of smell occurs very early in the process
and also occurs to a lesser degree in normal aging (Larsson
et al 1999; Peters et al 2003). In Alzheimer’s disease (AD),
degeneration occurs in the entorhinal-hippocampal-subicular
complex, and the neurons of the olfactory neuroepithelium
show numerous neurofibrillary tangles (Talamo et al 1989;
Royet et al 2001) which may partially explain olfactory
dysfunction. Brain imagining methods such as magnetic
resonance imaging (MRI) and positron emission tomography
(PET) have detected subtle structural changes early in MCI
and during progression to AD (Graves et al 1999; Kantarci
et al 2000). Chertkow (2002) described very early structural
changes in the entorhinal cortex leading to olfactory deficits
which have been detected by these imaging methods before
any measurable change in cognition.
Information associating olfactory decline with MCI is
limited; however, Devanand et al (2000) report that individuals
with MCI have olfactory identification deficits and lack
awareness of these deficits. Several chemical substances,
disease states, and treatment procedures affect the sense of
smell. Examples include α-interferon treatment, cocaine
(when insufflated), nifedipine, tobacco products, and
antineoplastic agents for cancer treatment. Among conditions
associated with anosmia are those affecting the central nervous
system, such as stroke, head trauma, brain tumors, and
Parkinsonism, diabetes mellitus, aneurysm, artery rupture,
allergic rhinitis, (Ackerman and Nishamony 1997) as well as
nasal obstruction.
MCI diagnosis
Increasing progress is being made in our understanding of
the disease process underlying dementia as well as the design
of novel therapeutic agents which may slow or possibly
prevent the progression of the disease. Yet studies show a
widespread failure to recognize dementias in their early stages.
Relkin (2000) reported studies that found primary care
physicians failed to recognize dementia in 24%–72% of
known cases and that general practitioners recognized MCI
in only 3.2% of cases.
Early detection of MCI would allow the maximum use of
potential therapeutic intervention before irreversible neuronal
damage has occurred. There is a need to develop ways to
detect early cognitive deficits long before symptoms of
dementia such as objective memory impairment are apparent
(Karlawish and Clark 2003). Unfortunately, currently
available non-invasive measures such as the Mini-Mental State
Exam (MMSE) (Folstein et al 1975) have not been adequate
to measure small changes in cognition (Salmon et al 2002;
Boeve et al 2003) or to distinguish between MCI and
depression (Bensen et al 2005). By correlating and combining
the discriminating power of the UPSIT and ACE, we were
able to detect signs of MCI.Neuropsychiatric Disease and Treatment 2006:2(4) 567
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Methods
Subjects
Investigators recruited volunteers over the age of 45 years from
a number of senior housing complexes, senior centers, a local
university, and local churches. A prescreening process excluded
from the study individuals who smoked, had selective medical
conditions or used medication (see Appendix) that might
interfere with olfaction. The final sample of 54 subjects was
comprised of 37 females and 17 males. The ages of the subjects
ranged from 46 to 91 with the median being 67 years of age.
The educational level ranged from 7 to 24 years of formal
schooling, with the median being 15 years.
Instruments
Cognition
The Addenbrooke’s Cognitive Examination was used in this
study to distinguish those subjects with MCI from the total
sample population. It is a validated instrument which can be
used to detect dementia and mild cognitive impairment
(Mathuranath et al 2000). In studies completed by
Mathuranath et al (2000, p 1619), “age, number of years of
education, or gender did not influence the predictive outcome
using the ACE”.
The ACE consists of 22 scored items with an emphasis
on measuring episodic memory, executive function, and
language ability. The ACE also incorporates the MMSE in its
entirety. The ACE evaluates 6 discrete cognitive domains:
orientation, attention, memory, verbal fluency, language, and
visual-spatial ability. Scores for each domain are calculated
and combined for an ACE total score. Past studies have shown
the ACE to be 82% sensitive and 96% specific in detecting
early dementias. Developers of the ACE used Chronbach’s
alpha coefficient of internal consistency to measure reliability.
“The Chronbach’s alpha for the ACE was 0.78.” (Mathuranath
et al 2000, p 1616).
The ACE total score ranges from 0 to 100. To identify
subjects with MCI, researchers used an ACE calculation called
the VL/OM to eliminate subjects who might have dementia.
The VL/OM, calculated by summing the scores on the verbal
fluency and language sections on the ACE and dividing by
the sum of the orientation and delayed recall sections,
identified and eliminated subjects with probable Alzheimer’s
disease and frontotemporal dementias.
 To identify MCI, Mathuranath et al (2000, p 1618)
recommend using a “cut off score of 83…for research
studies…which require high specificity, or when screening
populations with low base rate dementia”. Test developers
(Mathuranath et al 2000) selected 83 from the ACE total score
of 100 by estimating the probability of accurately diagnosing
dementia in their criterion group.
In addition, the diagnostic criteria for MCI require normal
general cognitive function. Following the ACE
recommendations, researchers eliminated subjects scoring
below one standard deviation on the ACE total score mean
(less than 84). Finally, to meet the criteria of objective memory
impairment, subjects whose score on delayed-recall items on
the ACE was one standard deviation below the predicted score
for their age and/or educational level were selected for
inclusion in the selected MCI group.
Olfaction
The University of Pennsylvania Smell Identification Test
(UPSIT) is a 40-item “scratch-and-sniff” odor identification
panel which has been used to identify individuals with
dementia. The UPSIT consists of 4 booklets, each containing
10 odorants. Odorants are released by scratching the strips in
which they are embedded with a pencil tip. Subjects are asked
to select the odorant from a list of 4 choices. A forced-choice
format is used in which subjects are asked to mark 1 of the 4
alternatives, even if they report not being able to perceive an
odorant. This procedure reduces the dependence on working
memory and language (Peters et al 2003). The normal range
of scores (number of correct responses out of a possible 40)
on the UPSIT for males is 34–40 and 35–40 for females. The
test-retest and split-half reliability have consistently been
found to be over 0.90 (Doty et al 1984; Doty 2000).
Data collection
Prior to data collection to improve inter-rater reliability,
researchers tested procedures by video taping administration
of the ACE to 5 community volunteers. Video tapes were
compared and protocols written for research testing. Five
members of the research team collected data from June–
October 2002 at senior housing complexes, senior centers,
churches, and in a university building. To maximize
consistency, 3 investigators administered the ACE to all
participants and two investigators administered the UPSIT
exclusively. The order of administration of these two
instruments was randomly assigned. Responses to the
ACE were entered on a score sheet by the interviewer.
Subjects recorded their own responses to the 40 items on
the UPSIT.Neuropsychiatric Disease and Treatment 2006:2(4) 568
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Data analysis
Data analysis included calculations of descriptive statistics
for all variables and split-half reliability coefficients for each
instrument. In addition, the data were analyzed to identify
individuals who met the diagnostic criteria for mild cognitive
impairment. This step eliminated 7 subjects who scored in
the dementia range on the ACE. To ensure our MCI sample
did not include persons with dementia, we also eliminated 6
subjects with ACE total scores below 84, one standard
deviation below the mean. A new ACE variable was created
by combining the scores on the two delayed recall items with
a possible range of 0–10. Using the ACE criterion, subjects
whose score on this variable was one standard deviation below
the predicted score for their age and/or educational level were
classified as the MCI subgroup. A step-wise binary regression
model was constructed using the dichotomous MCI-normal
classification as the dependent variable and scores on the
UPSIT as independent variables. The purpose of this analysis
was to establish a “best predictor” model whereby the highest
percentage of cases could be correctly classified with respect
to being in the MCI or normal groups. Kappa statistics were
calculated to determine if group membership was due to
chance.
The final stage in the analysis was to examine the extent
to which the UPSIT could accurately predict group
membership (MCI vs normal). In this stage, we ran two
stepwise regressions. In the first, the total UPSIT score was
used as covariate (independent variable), and in the second,
35 of the individual odors on the UPSIT were entered as
covariates using the stepwise method.
Results
ACE
ACE scores for all subjects ranged from 49 to100, with a
mean of 90.6, a median of 94, and a standard deviation of
3.4. Age had a significant negative correlation with the total
score (r = –0.53, p = 0.001); education had a significant positive
correlation with this score (r = 0.43, p = 0.002). Males scored
significantly higher than females with means being 93.7 and
89.1 respectively (t = 2.19, df = 48, p = 0.03).
The VL/OM calculation identified two subjects with
probable Alzheimer’s disease and five subjects with probable
frontotemporal dementia. These 7 subjects were eliminated
from our analysis.
UPSIT
UPSIT scores for all subjects ranged from 24 to 38 with a
mean of 32.8, a median of 33.5, and a standard deviation of
2. Scores were significantly related to the ACE total score
(r = 0.37, p = 0.005). There was a negative correlation with
age (r = –0.35, p = 0.01), and a positive correlation with
education (r = 0.35, p = 0.01). Gender was not significantly
related to the total score on the UPSIT.
Table 1 presents the demographic breakdown of the final
groups and their scores on the ACE and UPSIT. The MCI
group included 2 males and 5 females; the normal group
included 13 males and 21 females. Correlations between the
demographic variables and the total scores on the ACE and
UPSIT are shown in Table 2.
Motor oil, gasoline, leather, root beer, and peanut were
excluded from the analysis because all of the subjects correctly
identified them. The results of this stage suggest that four
specific odors (mint, chocolate, lime, and cheddar cheese) of
the 40 odorants of the UPSIT best predict the presence of MCI
(see Table 3) in older individuals. A Kappa statistic was
calculated to assess the extent to which the prediction model
predicted MCI-Normal group membership taking chance
agreements in group membership. The Kappa statistic was 0.61,
p < 0.0001, indicating that the model generated a better than
61% improvement in prediction over chance.
Discussion
The primary findings of this exploratory study are that
community-dwelling older individuals with probable MCI
lack the ability to identify a small group of odorants (mint,
Table 1  Age, education, ACE, and UPSIT Scores for MCIa and normalb groups
Age Education   ACE UPSIT
MCI Normal MCI Normal MCI Normal MCI Normal
70.71 64.03 15.00 16.12 91.14 95.21 33.14 33.50
(8.16) (11.44) (3.11) (3.54) (2.48) (2.97) (2.19) (3.05)
Note: Mean values are reported with standard deviations. 
an = 7 
bn = 34.
Abbreviations: ACE,  Addenbrooke’s Cognitive Examination; MCI, mild cognitive impairment; UPSIT, University of Pennsylvania Smell Identification Test.Neuropsychiatric Disease and Treatment 2006:2(4) 569
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lime, chocolate, and cheddar cheese); whereas all subjects,
regardless of cognitive status, can correctly identify a different
group of odorants (motor oil, gasoline, leather, root beer and
peanut). This finding suggests that a small selective group of
odorants can be used as a quick, easy, non-invasive tool to
identify individuals with MCI. The advantages of early
diagnosis include earlier treatment to prevent or delay
neuronal damage associated with dementias such as
Alzheimer’s and allowing individuals with MCI time to seek
available services and make future living decisions.
The ACE demonstrated its usefulness as an instrument.
ACE total score identified 7 subjects of 54 (13%)
community-dwelling individuals, between 49 and 91 years
of age, with probable MCI. This is an important finding
since nearly half of individuals with MCI tend to develop
dementia within three years (Grundman et al 1996). The
prevalence of MCI in our subjects over sixty-five was 19.4%,
which is well within the range of most previously reported
prevalence rates (Grundman et al 1996). ACE total score was
able to distinguish among normal subjects, 2 subjects (3.7%)
with probable Alzheimer’s disease, and 5 subjects (9.3%)
with probable frontotemporal dementia. Alzheimer’s and
frontotemporal dementias represented 13% of our total
sample of community-dwelling elders which approaches the
prevalence rates of 14.5 to 26.2% for lifetime risk of
Alzheimer’s reported by Chertkow (2002).
The results of this study demonstrate the need to adjust scores
on cognitive assessments such as the ACE for age and education
before applying them to screening criteria. The ACE total score
showed a positive correlation with years of education and a
significant negative correlation with age. Gender was not
significantly related to the full scale score on the UPSIT which
is not consistent with findings by Peters et al (2003); males,
however, scored significantly higher than females on the ACE.
 The UPSIT total scores showed a significantly negative
correlation with age. Using age-adjusted total scores did not
improve the predictive ability of the UPSIT.
This exploratory study had several limitations. The
small sample of individuals (n = 7) with MCI was drawn
from a regional population of convenience, rather than by
random selection. Investigators were unable to ascertain if
fatigue was a factor in subject performance. Administration
of the complete UPSIT and complete ACE required
concentration and took approximately 1 hour, a long time for
subjects unaccustomed to such activities. Another limitation
was the diversity of testing environments. Distractions in the
various community-based environments may have effected
how subjects responded to the ACE and UPSIT.
In conclusion, by administering the UPSIT, four
specific odorants (mint, lime, chocolate, and cheddar cheese)
were found to be predictive of MCI, as defined by ACE total
score in community-dwelling older individuals. These
selective 4 odorants proved to be better predictors of MCI
than UPSIT total scores.
 Studies by Peters et al (2003) and Tabert et al (2006)
highlight the importance of evaluating dysfunction in olfaction
and specific areas of cognition to identify individuals prior to
Table 2  Intercorrelations between age, education, and scores on the ACE, UPSIT, and MMSE for all subjects
Variable Age Education MMSE
a ACE UPSIT
Age — –0.23 –0.18 –0.34
* –0.44
**
Educat — 0.47** 0.62** 0.23
MMSE
a — 0.67
** 0.26
ACE — 0.29
Note: n = 41 
aThe MMSE is embedded in ACE. 
*p < 0.05, two-tailed. 
* *p < 0.01, two-tailed.
Abbreviations: ACE,  Addenbrooke’s Cognitive Examination; MMSE, Mini Mental State Examination; UPSIT, University of Pennsylvania Smell Identification Test.
Table 3  Predictive ability of UPSIT total score versus selective
odorants
UPSIT Selective
total score
a odorants
b,c
MCI group
Predicted 0 4
Actual 7 7
Sensitivity 0.0% 57.1%
Normal group
Predicted 34 33
Actual 34 34
Specificity 100% 97.1%
Note: Predicted and actual values are numbers of subjects.
aThe Nagelkerke R
2 estimator for this model was 0.0.
bFour odors (mint, chocolate, cheddar cheese, and lime) were entered
in the model.
cThe Nagelkerke R
2 estimator for this model was 0.50.
Abbreviations: MCI, mild cognitive impairment; UPSIT, University of
Pennsylvania Smell Identification Test.Neuropsychiatric Disease and Treatment 2006:2(4) 570
Kirkpatrick et al
Alzheimer’s disease. Future studies would require larger, more
diverse populations from community settings to substantiate
our exploratory study results. One research direction would
be to identify a subset of items in the ACE and UPSIT with the
greatest predictive value to increase the sensitivity and
specificity to develop a useful, less time consuming, test for
clinicians.
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Appendix
Medications and medical conditions included in exclusion
criteria.
Medications
Topical nasal vasoconstrictors (Afrin
®)
Cocaine
Nifedipine (Adalate
®, Procardia
®)
Cancer medications
Medical conditions
Nasal infections (colds, flu, stuffy nose)
History of smoking
History of stroke
Diabetes mellitus
Brain tumor
History of head trauma
Parkinsonism